MUSETTINI, GIANNA
 Distribuzione geografica
Continente #
NA - Nord America 965
EU - Europa 387
AS - Asia 207
AF - Africa 59
OC - Oceania 1
SA - Sud America 1
Totale 1.620
Nazione #
US - Stati Uniti d'America 944
IT - Italia 117
CN - Cina 93
SE - Svezia 89
SG - Singapore 70
GB - Regno Unito 50
DE - Germania 44
CI - Costa d'Avorio 41
BG - Bulgaria 40
CA - Canada 21
VN - Vietnam 16
SN - Senegal 15
FI - Finlandia 13
RU - Federazione Russa 10
TR - Turchia 9
KR - Corea 7
FR - Francia 6
HK - Hong Kong 6
UA - Ucraina 6
IN - India 3
AT - Austria 2
CH - Svizzera 2
ES - Italia 2
NG - Nigeria 2
NL - Olanda 2
AU - Australia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BR - Brasile 1
CZ - Repubblica Ceca 1
IR - Iran 1
KZ - Kazakistan 1
PL - Polonia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 1.620
Città #
Woodbridge 153
Ann Arbor 129
Houston 99
Chandler 79
Fairfield 79
Ashburn 54
Abidjan 41
Sofia 40
New York 33
Seattle 31
Beijing 30
Wilmington 30
Cambridge 25
Princeton 24
Santa Clara 24
Lancaster 23
Florence 22
London 22
Milan 22
Frankfurt am Main 19
Ottawa 19
Boardman 18
Singapore 18
Lawrence 17
Pisa 17
Dakar 15
Dearborn 15
Medford 12
Des Moines 10
Düsseldorf 10
Nanjing 8
Fuzhou 7
Istanbul 7
Los Angeles 7
San Diego 7
Hong Kong 6
Shenyang 5
Wuhan 5
Hebei 4
Ogden 4
Piombino 4
Shanghai 4
Serra 3
Besencens 2
Bremen 2
Canino 2
Dong Ket 2
Genoa 2
Grafing 2
Hefei 2
Jiaxing 2
Kunming 2
Lagos 2
Livorno 2
Positano 2
Quanzhou 2
Romainville 2
Rome 2
Seacroft 2
Shenzhen 2
Strasbourg 2
Toronto 2
Vienna 2
Almaty 1
Baku 1
Bratislava 1
Buffalo 1
Campi Bisenzio 1
Canberra 1
Casaleone 1
Castell'azzara 1
Changsha 1
Chengdu 1
Cotonou 1
Edinburgh 1
Ferrara 1
Freiburg 1
Guangzhou 1
Helsinki 1
Hyderabad 1
Massa 1
Minerbio 1
Munich 1
Nanchang 1
New Bedfont 1
Newhall 1
Olomouc 1
Phoenix 1
Pietrasanta 1
Redwood City 1
Rosignano Marittimo 1
San Francisco 1
San Giuliano Terme 1
Sarajevo 1
Simonésia 1
St Louis 1
Torino 1
Viareggio 1
Vicopisano 1
Warsaw 1
Totale 1.278
Nome #
Second-line therapy for advanced pancreatic cancer: Evaluation of prognostic factors and review of current literature 129
Is there a role for palliative gastrectomy in asymptomatic metastatic gastric cancer? 127
Impact of a supportive care service for cancer outpatients: management and reduction of hospitalizations. Preliminary results of an integrated model of care 116
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors 114
The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer 112
Correlation between LDH levels and response to sorafenib in HCC patients: An analysis of the ITA.LI.CA database 109
Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer. 106
EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected adenocarcinomas of the stomach and gastro-esophageal junction 102
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data 95
HER2 overexpression as a poor prognostic determinant in resected biliary tract cancer 95
Prognostic model for patients (PTS) with advanced pancreatic cancer (aPC) receiving first-line modified FOLFIRINOX (Mfolfirinox) 86
Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan 85
Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (PTS) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now? 82
Pharmacoepigenetics in gastrointestinal tumors: MGMT methylation and beyond 77
Palliative gastrectomy in asymptomatic metastatic esophagogastric cancer (EGC): does it make sense? 72
Single-centre experience with third-line chemotherapy with irinotecan plus 5-fluorouracil and leucovorin (FOLFIRI) in metastatic gastric cancer patients. 65
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 47
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 37
Totale 1.656
Categoria #
all - tutte 5.122
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.122


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020152 0 0 0 0 15 29 29 19 20 13 24 3
2020/202188 6 6 5 0 1 3 5 9 5 22 5 21
2021/2022198 1 5 2 2 44 28 4 4 14 8 19 67
2022/2023314 23 57 21 4 29 27 0 17 99 3 31 3
2023/2024174 8 15 27 7 26 28 18 7 2 7 12 17
2024/2025104 0 19 20 36 29 0 0 0 0 0 0 0
Totale 1.656